PHAT
NASDAQ · Pharmaceuticals
Phathom Pharmaceuticals Inc
$10.06
-0.51 (-4.83%)
Financial Highlights (FY 2026)
Revenue
70.96M
Net Income
-429,389,693
Gross Margin
85.6%
Profit Margin
-605.1%
Rev Growth
—
D/E Ratio
1.24
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 85.6% | 65.8% | 65.8% | 65.8% |
| Operating Margin | -502.2% | 37.3% | 39.2% | 42.8% |
| Profit Margin | -605.1% | 30.0% | 28.4% | 28.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 70.96M | 173.93M | 162.51M | 174.28M |
| Gross Profit | 60.72M | 114.44M | 106.93M | 114.67M |
| Operating Income | -356,369,611 | 64.83M | 63.74M | 74.56M |
| Net Income | -429,389,693 | 52.15M | 46.06M | 49.26M |
| Gross Margin | 85.6% | 65.8% | 65.8% | 65.8% |
| Operating Margin | -502.2% | 37.3% | 39.2% | 42.8% |
| Profit Margin | -605.1% | 30.0% | 28.4% | 28.3% |
| Rev Growth | — | -4.6% | -5.1% | +14.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 259.84M | 290.01M | 278.72M | 245.03M |
| Total Equity | 209.14M | 430.20M | 411.26M | 463.12M |
| D/E Ratio | 1.24 | 0.67 | 0.68 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -355,349,993 | 99.13M | 88.44M | 98.15M |
| Free Cash Flow | — | 45.89M | 35.44M | 36.11M |